ANXA1 and breast carcinoma: In order to further confirm our findings, ANXA1 and CALD1 protein levels were assessed through IHC staining on an independent cohort of 408 FFPE tumor tissues derived from patients that received tamoxifen as first line therapy for recurrent breast cancer (Table S3).